Alkaline hypertonic ibuprofenate increases platelets in COVID-19 patients

Summaries 3 min 313

Font Size

Created On: 16/10/2021

Alkaline hypertonic ibuprofenate increases platelets in COVID-19 patients

This study determined alterations in platelets in coronavirus-positive people who received conventional therapy enoxaparin and dexamethasone vs. people treated with the combination of conventional therapy and nebulization with alkaline hypertonic ibuprofenate.

See All

Key take away

Nebulization with alkaline hypertonic ibuprofenate triggers an expeditious rise in platelets circulating in SARS-CoV-2 patients but not in healthy volunteers.

Background

Method

In this study, the change in the levels of circulating platelets via alkaline hypertonic ibuprofenate was assessed. To check if this action was associated with platelets from coronavirus-positive subjects or also for healthy subjects, 2 controls were incorporated: 1 of them with ten healthy volunteers and another one with coronavirus-positive subjects hospitalized and treated only with dexamethasone and enoxaparin.

Result

Table 1 shows a rise in the circulating platelets following twenty-four hours of nebulization with alkaline hypertonic ibuprofenate, in people having platelets content below 200,000 by microliter and above 200,000 by microliter.

Both males and females showed a comparable rise in the levels of circulating platelets via alkaline hypertonic ibuprofenate. It was found that in healthy people, the number of circulating platelets remains unaltered even after seven days of therapy with alkaline hypertonic ibuprofenate. In coronavirus-positive people treated only with dexamethasone and enoxaparin for four days, only a 16% increase in platelets was noted.